Results 111 to 120 of about 2,077,438 (389)

Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer   +14 more
wiley   +1 more source

Exploratory Analysis of ELP1 Expression in Whole Blood From Patients With Familial Dysautonomia

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Familial dysautonomia (FD) is a hereditary neurodevelopmental disorder caused by aberrant splicing of the ELP1 gene, leading to a tissue‐specific reduction in ELP1 protein expression. Preclinical models indicate that increasing ELP1 levels can mitigate disease manifestations.
Alejandra González‐Duarte   +13 more
wiley   +1 more source

The geographic spread of the CCR5 Delta32 HIV-resistance allele.

open access: yesPLoS Biology, 2005
The Delta32 mutation at the CCR5 locus is a well-studied example of natural selection acting in humans. The mutation is found principally in Europe and western Asia, with higher frequencies generally in the north.
John Novembre   +2 more
doaj   +2 more sources

Lalkarz Jurkowski (1927–2016)

open access: yesPamiętnik Teatralny, 2016
Memory of Henryk Zdzisław Jurkowski (1927–2016), a puppet theatre historian, theorist and critic, pedagogue, dramatist, editor, and long-time Polish representative in UNIMA (Union Internationale de la Marionnette), officer of the Union’s governing bodies
Marek Waszkiel
doaj   +1 more source

Screening for prostate cancer: History, evidence, controversies and future perspectives toward individualized screening

open access: yesInternational journal of urology, 2019
Differences in the incidence and mortality rate of prostate cancer between the USA and Japan have been decreasing over time, and were only twofold in 2017.
Kazuto Ito   +7 more
semanticscholar   +1 more source

Use of Symptomatic Drug Treatment for Fatigue in Multiple Sclerosis and Patterns of Work Loss

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe the use of central stimulants and amantadine for fatigue in MS and evaluate a potential association with reduced work loss in people with MS. Methods We conducted a nationwide, matched, register‐based cohort study in Sweden (2006 to 2023) using national registers with prospective data collection.
Simon Englund   +3 more
wiley   +1 more source

L’Europa e il Mediterraneo: percorsi di ricerca transnazionali e spazi online [PDF]

open access: yesDiacronie. Studi di Storia Contemporanea, 2016
This paper is a reasoned review of the main’s cultural institutes websites working about Mediterranean Europe, with a reading that links political economic dimension with that of communication to verify the state of research and study’s transnational ...
Sante Cruciani , Raffaello Ares Doro
doaj  

The Reformation as a Factor of New Time in the European History (to the 500th Anniversary of the Reformation in Europe) [PDF]

open access: yes, 2017
У статті висвітлюється місце та роль Реформації в європейській історії XVI-XVII ст. Проаналізовано чинники, які сприяли появі реформаційного руху в Європі. Охарактеризовано основні течії протестантизму.
Kramar, Yurii, Крамар, Ю. В.
core  

A survey of articles in the Newsletter of the EMS about the history and activities of full member Societies of the EMS (Issue 1, September 1991 – Issue 104, June 2017) [PDF]

open access: yes, 2017
In order to have a clearer idea of what has been published and so to be able to plan future actions, the Editorial Board of the Newsletter has recently compiled a survey of articles on the history and activities of full member societies of the EMS.
Costa, Fernando Pestana da
core   +1 more source

Home - About - Disclaimer - Privacy